Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harlequin syndrome: segmental autonomic dysfunction in the realm of Sjogren's disease.

Rheumatology (Oxford, England)·2026
Same author

Unifying theories in high-dimensional biophysics: approaches, challenges and opportunities.

NPJ systems biology and applications·2026
Same author

Hypertension Management Beyond Blood Pressure Control in India: An Expert Consensus on Angiotensin II Receptor Blocker and Calcium Channel Blocker Combination Therapy With Reference to Telmisartan and Cilnidipine.

Cureus·2026
Same author

Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models.

Research square·2026
Same author

Shared multicellular injury programs of acute and chronic kidney disease enable mechanistic patient stratification.

medRxiv : the preprint server for health sciences·2026
Same author

Invasive mould infections of the central nervous system in the Indian population: a cohort study (2004-2025).

The Lancet regional health. Southeast Asia·2026
Same journal

The NTP Chronic Inhalation Study Does Not Support an Inherent Lung Cancer Hazard of Talc: Implications of Lung Particle Overload and Maximum Tolerated Dose.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Consideration of Carcinogenicity and Mode of Action Information by an Independent Expert Panel to Support Derivation of No-Significant-Risk-Level Values for Vinyl Acetate Monomer.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Which carcinogenicity study should I use? Automated identification of reliable studies.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Adoption of artificial intelligence in drug review across the lifecycle: Transformation of regulatory decision-making.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Cardiovascular outcomes following intrauterine and lactational exposure to cyantraniliprole in male Wistar rats.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Pesticide residue and mycotoxin occurrence in apples and their impact on human health in Morocco.

Regulatory toxicology and pharmacology : RTP·2026
See all related articles

Related Experiment Video

Updated: Jul 12, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Carcinogenicity testing in drug development: Getting it right.

Paul Baldrick1, Sanjay Jain1

  • 1Product Development and Market Access Consulting, Fortrea, 5 Foundation Park, Roxborough Way, Maidenhead, SL6 3UD, United Kingdom(1).

Regulatory Toxicology and Pharmacology : RTP
|October 25, 2023
PubMed
Summary
This summary is machine-generated.

Pharmaceutical carcinogenicity testing in rodents informs human risk assessment. Regulatory interactions, like the FDA

Keywords:
CarcinogenicityDose level selectionMouseRatRegulatory agencyTransgenic mouse

More Related Videos

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

6.8K
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

14.4K

Related Experiment Videos

Last Updated: Jul 12, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

6.8K
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

14.4K

Area of Science:

  • Regulatory science
  • Toxicology
  • Pharmaceutical development

Background:

  • Carcinogenicity testing in rodents is crucial for assessing pharmaceutical drug risks in humans.
  • Standard testing involves 2-year rodent studies or 6-month transgenic mouse studies.
  • Regulatory engagement, such as the US FDA's Special Protocol Assessment (SPA), is key for protocol approval.

Purpose of the Study:

  • To examine regulatory interactions concerning pharmaceutical carcinogenicity testing protocols.
  • To analyze the outcomes of agency engagement, focusing on dose selection and study design.
  • To evaluate the effectiveness of the current regulatory process for drug approval.

Main Methods:

  • Analysis of 37 submissions to the Carcinogenicity Assessment Committee (CAC).
  • Examination of regulatory interactions, including the FDA's Special Protocol Assessment (SPA) process.
  • Review of study design aspects: animal numbers, control groups, and toxicokinetic (TK) evaluation.

Main Results:

  • The current regulatory interaction process generally yields acceptable carcinogenicity studies for drug approval.
  • Analysis revealed specific areas for improvement in submission content and study design.
  • Key outcomes included insights into study dose level selection and protocol elements.

Conclusions:

  • The existing regulatory framework supports the development of acceptable carcinogenicity studies for drug marketing.
  • Opportunities exist to enhance the quality of submission documents and the design of carcinogenicity studies.
  • Continued refinement of regulatory interactions can further optimize the drug development and approval process.